Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics
Related Experiment Video
Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Leslie Z Benet1, Hsin-Fang Wu1
1Department of Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco 94143, California.
Abstract:
Here we address the potential difference in rosuvastatin pharmacokinetics in Asians vs. whites. Our prospective study, reported in this issue, shows no ethnic difference when all subjects are wild-type for OATP1B1 and BCRP. We argue that although our study may be under powered to prove no ethnic difference, and that further confirmatory study is required, the virtual clinical study analysis, also reported in this issue, does not contradict the results of our prospective clinical study and that previous retrospective analysis of clinical studies does not include enough relevant subjects to conclude that wild-type OATP1B1 and BCRP do still demonstrate ethnic differences.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug toxicity: Idiosyncratic Reactions
Dosage Regimen: Individualization

